Inosine and equilibrative nucleoside transporter 2 contribute to hypoxic preconditioning in the murine cardiomyocyte HL-1 cell line

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 294, Issue 6, 2008, Pages

  Naydenova, Zlatina ^a   Rose, Jennifer B ^a   Coe, Imogen R ^a  

^a YORK UNIVERSITY   (Canada)

Author keywords

Equilibrative nucleoside transporters; Heart; Hypoxia; Purine nucleosides; Regulation

Indexed keywords

8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A3 RECEPTOR; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; INOSINE; 1,3-DIPROPYL-8-CYCLOPENTYLXANTHINE; 4-NITROBENZYLTHIOINOSINE; DRUG DERIVATIVE; MERCAPTOPURINE RIBOSIDE; NITROBENZYLTHIOINOSINE; NUCLEOSIDE TRANSPORTER; QUINAZOLINE DERIVATIVE; SLC29A1 PROTEIN, MOUSE; SLC29A2 PROTEIN, MOUSE; TRIAZOLE DERIVATIVE; XANTHINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL HYPOXIA; CONTROLLED STUDY; HEART MUSCLE CELL; HYPOXIC PRECONDITIONING; ISCHEMIC PRECONDITIONING; MOUSE; NONHUMAN; NUCLEOSIDE TRANSPORT; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; CELL LINE; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY; UPREGULATION;

ADENOSINE; ANIMALS; CELL HYPOXIA; CELL LINE; CELL SURVIVAL; EQUILIBRATIVE-NUCLEOSIDE TRANSPORTER 2; INOSINE; MICE; MYOCYTES, CARDIAC; NUCLEOSIDE TRANSPORT PROTEINS; QUINAZOLINES; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A3; THIOINOSINE; TRIAZOLES; UP-REGULATION; XANTHINES;

EID: 49249115881     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00251.2007     Document Type: Article

References (34)

1. Ardehali H. Signaling mechanisms in ischemic preconditioning: interaction of PKCepsilon and MitoK (ATP) in the inner membrane of mitochondria. Circ Res 99: 798-800, 2006.
2. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflügers Arch 447: 735-743, 2004.
3. Blackburn MR. Too much of a good thing: adenosine overload in adenosine-deaminase-deficient mice. Trends Pharmacol Sci 24: 66-70, 2003.
4. Chaudary N, Shuralyova I, Liron T, Sweeney G, Coe IR. Transport characteristics of HL-1 cells; a new model for the study of adenosine physiology in cardiomyocytes. Biochem Cell Biol 80: 655-665, 2002.
5. Chaudary N, Naydenova Z, Shuralyova I, Coe IR. PKCε regulates ischemic preconditioning and the adenosine transporter, mENT1, in the mouse cardiac myocyte cell line, HL-1. J Pharmacol Exp Ther 310: 1190-1198, 2004.
6. Chaudary N, Naydenova Z, Shuralyova I, Coe IR. Hypoxia regulates the adenosine transporter, mENT1, in the murine cardiomyocyte cell line, HL-1. Cardiovasc Res 61: 780-788, 2004.
7. Chen P, Goldberg DE, Kolb B, Lanser M, Benowitz LI. Inosine induces axonal requiring and improves behavioral outcome after stroke. Proc Natl Acad Sci USA 99: 9031-9036, 2002.
8. Crawford CR, Patel DH, Naeve C, Belt JA. Cloning of the human equilibrative, nitrobenzylmercaptopurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell Line. J Biol Chem 273: 5288-5293, 1998.
9. de Jong JW, de Jonge R, Keijzer E, Bradamante S. The role of adenosine in preconditioning. Pharmacol Ther 87: 141-149, 2000.
10. Gayden RH, Watts 3rd BA, Beach RE, Benedict CR. Quantitation of adenosine, inosine and hypoxanthine in biological samples by microbore-column isocratic high-performance liquid chromatography. J Chromatogr 536: 265-272, 1991.
11. Goldhaber SZ, Pohost GM, Kloner RA, Andrews E, Newell JB, Ingwall JS. Inosine: a protective agent in an organ culture model of myocardial ischemia. Circ Res 51: 181-188, 1982.
12. Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, SLC28. Pflügers Arch 447: 728-734, 2004.
13. Hasko G, Sitkovsky MV, Szabo C. Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol Sci 25: 152-157, 2004.
14. Headrick JP. Ischemic preconditioning: bioenergetic, and metabolic changes, and the role of endogenous adenosine. J Mol Cell Cardiol 27: 1041-1054, 1996.
15. Ishida T, Yarimizu K, Gute DC, Korthuis RJ. Mechanisms of ischemic preconditioning. Shock 8: 86-94, 1997.
16. Jin X, Shepherd RK, Duling BR, Linden J. Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J Clin Invest 100: 2849-2857, 1997.
17. Kobayashi S, Zimmermann H, Millhorn DE. Chronic hypoxia enhances adenosine release in rat PC12 cells by altering adenosine metabolism and membrane transport. J Neurochem 74: 621-632, 2000.
18. Luqman N, Sung RJ, Wang CL, Kuo CT. Myocardial ischemia and ventricular fibrillation: pathophysiology and clinical implications. Int J Cardiol 119: 283-290, 2007
19. Mubagawa K, Flameng W. Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc Res 52: 25-39, 2001.
20. Murray CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74: 1124-1136, 1986.
21. Nakano A, Cohen MV, Downey JM. Ischemic preconditioning: from basic mechanisms to clinical applications. Pharmacol Ther 86: 263-275, 2000.
22. Parkinson FE, Xiong W, Zamzow CR. Astrocytes and neurons: different roles in regulating adenosine levels. Neurol Res 27: 153-160, 2005.
23. Pennycooke M, Chaudary N, Shuralyova I, Zhang Y, Coe IR. Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun 280: 951-959, 2001.
24. Pouzet B, Lecharny JB, Dehoux M, Paquin S, Kitazake M, Mantz J, Menasche P. Is there a place for preconditioning during cardiac operations in humans? Ann Thorac Surg 73: 843-848, 2002.
25. Reichelt ME, Willems L, Molina JG, Sun CX, Noble JC, Ashton KJ, Schnermann J, Blackburn MR, Headrick JP. Genetic deletion of the A1 adenosine receptor limits myocardial ischemic tolerance. Circ Res 96: 363-367, 2005.
26. Saks V, Favier R, Guzun R, Schlattner U, Wallimann T. Molecular system bioenergetics: regulation of substrate supply in response to heart energy demands. J Physiol 577: 769-777, 2006.
27. Schulz R, Cohen MV, Behrends M, Downey JM, Heusch G. Signal transduction of ischemic preconditioning. Cardiovasc Res 52: 181-198, 2001.
28. Shen H, Chen GJ, Harvey BK, Bickford PC, Wang Y. Inosine reduces ischemic brain injury in rats. Stroke 36: 654-659, 2005. Erratum. Stroke 36(5): 1112, 2005.
29. 3 receptors on mast cells. J Clin Invest 105: 361-367, 2000.
30. Wakai A, Winter DC, Street JT, O'Sullivan RG, Wang JH, Redmond HP. Inosine attenuates tourniquet-induced skeletal muscle reperfusion injury. J Surg Res 99: 311-315, 2001.
31. Ward JL, Sherali A, Mo ZP, Tse CM. Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. ENT2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine. J Biol Chem 275: 8375-8381, 2000.
32. Weiss JN, Yang L, Qu Z. Systems biology approaches to metabolic and cardiovascular disorders: network perspectives of cardiovascular metabolism. J Lipid Res 47: 2355-2366, 2006.
33. 1 receptor deficiency in normoxic and ischaemic mouse hearts. Cardiovasc Res 71: 79-87, 2006.
34. Yaar R, Jones MR, Chen JF, Ravid KJ. Animal models for the study of adenosine receptor function. J Cell Physiol 202: 9-20, 2005.